Literature DB >> 22290374

Effects of ipsapirone and cannabidiol on human experimental anxiety.

A W Zuardi1, R A Cosme, F G Graeff, F S Guimarães.   

Abstract

The effects of ipsapirone and cannabidiol (CBD) on healthy volunteers submitted to a simulated public speaking (SPS) test were compared with those of the anxiolytic benzodiazepine diazepam and placebo. Four independent groups of 10 subjects received, under a double-blind design, placebo or one of the following drugs: CBD (300 mg), diazepam (10 mg) or ipsapirone (5 mg). Subjective anxiety was evaluated through the Visual Analogue Mood Scale (VAMS) and the State-trait Anxiety Inventory (STAI). The VAMS anxiety factor showed that ipsapirone attenuated SPS-induced anxiety while CBD decreased anxiety after the SPS test. Diazepam, on the other hand, was anxiolytic before and after the SPS test, but had no effect on the increase in anxiety induced by the speech test. Only ipsapirone attenuated the increase in systolic blood pressure induced by the test. Significant sedative effects were only observed with diazepam. The results suggest that ipsapirone and CBD have anxiolytic properties in human volunteers submitted to a stressful situation.

Entities:  

Year:  1993        PMID: 22290374     DOI: 10.1177/026988119300700112

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  91 in total

Review 1.  Current application of cannabidiol (CBD) in the management and treatment of neurological disorders.

Authors:  Brian Fiani; Kasra John Sarhadi; Marisol Soula; Atif Zafar; Syed A Quadri
Journal:  Neurol Sci       Date:  2020-06-16       Impact factor: 3.307

2.  Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.

Authors:  Shanna Babalonis; Margaret Haney; Robert J Malcolm; Michelle R Lofwall; Victoria R Votaw; Steven Sparenborg; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2016-12-14       Impact factor: 4.492

Review 3.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

Review 4.  Modulation of the Endocannabinoid and Oxytocinergic Systems as a Potential Treatment Approach for Social Anxiety Disorder.

Authors:  Rafael Guimarães Dos Santos; Flávia de Lima Osório; Rocio Martin-Santos; Antonio Waldo Zuardi; Jaime Eduardo Cecilio Hallak; José Alexandre S Crippa
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

Review 5.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

6.  Cannabidiol in Anxiety and Sleep: A Large Case Series.

Authors:  Scott Shannon; Nicole Lewis; Heather Lee; Shannon Hughes
Journal:  Perm J       Date:  2019

7.  Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats.

Authors:  Erin M Rock; Cheryl L Limebeer; Gavin N Petrie; Lauren A Williams; Raphael Mechoulam; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2017-04-20       Impact factor: 4.530

Review 8.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

Review 9.  Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Authors:  José Alexandre S Crippa; Jaime E C Hallak; Antônio W Zuardi; Francisco S Guimarães; Vitor Tumas; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-31       Impact factor: 5.270

Review 10.  Pharmacological challenge studies with acute psychosocial stress.

Authors:  Kathryne Van Hedger; Anya K Bershad; Harriet de Wit
Journal:  Psychoneuroendocrinology       Date:  2017-08-22       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.